Related Experiment Videos
Electroconvulsive therapy in a patient receiving rivastigmine
Mathias Zink1, Alexander Sartorius, Florian Lederbogen
1Department of Psychiatry, Central Institute of Mental Health, Mannheim, Germany. zink@kv.zi-mannheim.de
The Journal of ECT
|October 24, 2002
Summary
Electroconvulsive therapy (ECT) combined with rivastigmine safely treated major depressive episodes in an elderly patient with early Alzheimer's disease. The combination therapy led to complete remission without cognitive decline or side effects.
Area of Science:
- Geriatric Psychiatry
- Neuroscience
- Pharmacology
Background:
- Major depressive episodes are common in elderly individuals, often co-occurring with neurodegenerative diseases like Alzheimer's disease.
- Electroconvulsive therapy (ECT) is a highly effective treatment for severe depression but carries risks of cognitive side effects, particularly in older adults.
- Acetylcholinesterase inhibitors (ACHE-I), such as rivastigmine, are used to manage cognitive symptoms in Alzheimer's disease.
Observation:
- An 81-year-old woman with major depressive episode and incipient Alzheimer's disease received right unilateral ECT.
- Treatment proceeded without interruption of her ongoing rivastigmine therapy.
- The patient achieved complete depressive remission after eight ECT sessions.
Findings:
- The patient experienced no significant memory or cognitive deterioration post-ECT.
- No notable cholinergic side effects were observed during the treatment course.
- This case suggests ECT can be safely administered to elderly patients with mild dementia on ACHE-I therapy.
Implications:
- Continuous ACHE-I therapy might mitigate adverse cognitive and cholinergic effects of ECT.
- This finding warrants further investigation in clinical trials to confirm the neuroprotective potential of ACHE-I during ECT.
- Optimizing treatment strategies for comorbid depression and dementia in the elderly is crucial for improving patient outcomes.